Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024

Rhea-AI Summary

Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care, has announced its participation in the Canaccord Genuity Growth Conference. Nick Colangelo, the company's President and CEO, is scheduled to present on Wednesday, August 14, 2024, at 3:00 p.m. ET.

This presentation offers an opportunity for investors and interested parties to gain insights into Vericel's operations and growth strategies. The company has made the event accessible to a wider audience by providing a webcast of the presentation, which will be available on the Investor Relations section of Vericel's official website at http://investors.vcel.com.

Vericel's participation in this conference underscores its commitment to transparency and engagement with the investment community, potentially impacting its market position and investor relations.

CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Growth Conference at 3:00 p.m. ET on Wednesday, August 14, 2024.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact: 
Julie Downs
media@vcel.com

FAQ

When is Vericel (VCEL) presenting at the Canaccord Genuity Growth Conference?

Vericel (VCEL) is presenting at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024, at 3:00 p.m. ET.

Who will be presenting for Vericel (VCEL) at the Canaccord Genuity Growth Conference?

Nick Colangelo, the President and CEO of Vericel , will be presenting at the Canaccord Genuity Growth Conference.

How can I watch Vericel's (VCEL) presentation at the Canaccord Genuity Growth Conference?

A webcast of Vericel's presentation will be available on the Investor Relations section of the Vericel website at http://investors.vcel.com.

What markets does Vericel (VCEL) operate in?

Vericel (VCEL) is a leader in advanced therapies for the sports medicine and severe burn care markets.